fda safety communication semaglutide naion 2025 drug MHRA Safety Alert: Semaglutide and Non-Arteritic Anterior Ischemic fda drug safety communication naion
Description
Clinicians should exercise caution in individuals with predisposing ocular risk factors, such as small Bruchs membrane opening (BMO), optic disc drusen (ODD), or otherwise crowded optic nerve heads
Retatrutide for advanced weight loss and metabolic support
PlexusDx explains how these medications interact with pregnancy planning and what research reveals about safety and conception
Semaglutide maintenance doses represent the therapeutic level where your body responds optimally to treatment
Michael Greger explores the science behind these medications and gives us the answers we need
